Talha Shaikh1, Elizabeth A Handorf2, Colin T Murphy1, Ranee Mehra3, John A Ridge4, Thomas J Galloway5. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 2. Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 3. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 4. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 5. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: Thomas.Galloway@fccc.edu.
Abstract
PURPOSE: To assess the impact of radiation treatment time (RTT) in head and neck cancers on overall survival (OS) in the era of chemoradiation. METHODS AND MATERIALS: Patients with diagnoses of tongue, hypopharynx, larynx, oropharynx, or tonsil cancer were identified by use of the National Cancer Database. RTT was defined as date of first radiation treatment to date of last radiation treatment. In the definitive setting, prolonged RTT was defined as >56 days, accelerated RTT was defined as <47 days, and standard RTT was defined as 47 to 56 days. In the postoperative setting, prolonged RTT was defined as >49 days, accelerated RTT was defined as <40 days, and standard RTT was defined as 40 to 49 days. We used χ2 tests to identify predictors of RTT. The Kaplan-Meier method was used to compare OS among groups. Cox proportional hazards model was used for OS analysis in patients with known comorbidity status. RESULTS: 19,531 patients were included; 12,987 (67%) had a standard RTT, 4,369 (34%) had an accelerated RTT, and 2,165 (11%) had a prolonged RTT. On multivariable analysis, accelerated RTT (hazard ratio [HR] 0.84; 95% confidence interval [CI] 0.73-0.97) was associated with an improved OS, and prolonged RTT (HR 1.25; 95% CI 1.14-1.37) was associated with a worse OS relative to standard RTT. When the 9,200 (47%) patients receiving definitive concurrent chemoradiation were examined, prolonged RTT (HR 1.29; 95% CI 1.11-1.50) was associated with a worse OS relative to standard RTT, whereas there was no significant association between accelerated RTT and OS (HR 0.76; 95% CI 0.57-1.01). CONCLUSION: Prolonged RTT is associated with worse OS in patients receiving radiation therapy for head and neck cancer, even in the setting of chemoradiation. Expeditious completion of radiation should continue to be a quality metric for the management of head and neck malignancies.
PURPOSE: To assess the impact of radiation treatment time (RTT) in head and neck cancers on overall survival (OS) in the era of chemoradiation. METHODS AND MATERIALS: Patients with diagnoses of tongue, hypopharynx, larynx, oropharynx, or tonsil cancer were identified by use of the National Cancer Database. RTT was defined as date of first radiation treatment to date of last radiation treatment. In the definitive setting, prolonged RTT was defined as >56 days, accelerated RTT was defined as <47 days, and standard RTT was defined as 47 to 56 days. In the postoperative setting, prolonged RTT was defined as >49 days, accelerated RTT was defined as <40 days, and standard RTT was defined as 40 to 49 days. We used χ2 tests to identify predictors of RTT. The Kaplan-Meier method was used to compare OS among groups. Cox proportional hazards model was used for OS analysis in patients with known comorbidity status. RESULTS: 19,531 patients were included; 12,987 (67%) had a standard RTT, 4,369 (34%) had an accelerated RTT, and 2,165 (11%) had a prolonged RTT. On multivariable analysis, accelerated RTT (hazard ratio [HR] 0.84; 95% confidence interval [CI] 0.73-0.97) was associated with an improved OS, and prolonged RTT (HR 1.25; 95% CI 1.14-1.37) was associated with a worse OS relative to standard RTT. When the 9,200 (47%) patients receiving definitive concurrent chemoradiation were examined, prolonged RTT (HR 1.29; 95% CI 1.11-1.50) was associated with a worse OS relative to standard RTT, whereas there was no significant association between accelerated RTT and OS (HR 0.76; 95% CI 0.57-1.01). CONCLUSION: Prolonged RTT is associated with worse OS in patients receiving radiation therapy for head and neck cancer, even in the setting of chemoradiation. Expeditious completion of radiation should continue to be a quality metric for the management of head and neck malignancies.
Authors: G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand Journal: J Natl Cancer Inst Date: 1999-12-15 Impact factor: 13.506
Authors: Donald M Cannon; Heather M Geye; Gregory K Hartig; Anne M Traynor; Tien Hoang; Timothy M McCulloch; Peggy A Wiederholt; Richard J Chappell; Paul M Harari Journal: Head Neck Date: 2013-11-27 Impact factor: 3.147
Authors: David I Rosenthal; Li Liu; Jason H Lee; Neha Vapiwala; Ara A Chalian; Gregory S Weinstein; Irina Chilian; Randal S Weber; Mitchell Machtay Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: Colin T Murphy; Thomas J Galloway; Elizabeth A Handorf; Lora Wang; Ranee Mehra; Douglas B Flieder; John A Ridge Journal: Cancer Date: 2014-12-09 Impact factor: 6.860
Authors: D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz Journal: N Engl J Med Date: 1998-06-18 Impact factor: 91.245
Authors: Evan M Graboyes; Elizabeth Garrett-Mayer; Mark A Ellis; Anand K Sharma; Amy E Wahlquist; Eric J Lentsch; Brian Nussenbaum; Terry A Day Journal: Cancer Date: 2017-08-25 Impact factor: 6.860
Authors: Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: Allen S Ho; Sungjin Kim; Mourad Tighiouart; Alain Mita; Kevin S Scher; Joel B Epstein; Anna Laury; Ravi Prasad; Nabilah Ali; Chrysanta Patio; Jon Mallen-St Clair; Zachary S Zumsteg Journal: Cancer Date: 2018-05-09 Impact factor: 6.860
Authors: Jeremy P Harris; Michelle M Chen; Ryan K Orosco; Davud Sirjani; Vasu Divi; Wendy Hara Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-04-01 Impact factor: 6.223
Authors: Musaddiq J Awan; Haley Gittleman; Jill Barnholtz-Sloan; Mitchell Machtay; Phuc Felix Nguyen-Tan; David I Rosenthal; Christopher Schultz; Bradley J Huth; Wade L Thorstad; Steven J Frank; Harold Kim; Robert L Foote; Miriam N Lango; George Shenouda; Mohan Suntharalingam; Jonathan Harris; Qiang Zhang; Quynh-Thu Le; Min Yao Journal: Oral Oncol Date: 2021-02-25 Impact factor: 5.337